Basic Information
| LncRNA/CircRNA Name | SPRY4-IT1 |
| Synonyms | SPRY4-IT1, SPRIGHTLY |
| Region | NA |
| Ensemble | ENSG00000281881 |
| Refseq | NR_131221 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, RNAi, Western blot, Flow cytometry assay etc. |
| Sample | NSCLC tissues, cell lines (A549, SPC-A1, NCI-H1975, NCI-H1299, NCI-H1650, SK-MES-1) |
| Expression Pattern | down-regulated |
| Function Description | In this study, we showed that epigenetic silencing of lncRNA SPRY4 intronic transcript 1 (SPRY4-IT1) occurs in non-small-cell lung cancer (NSCLC) cells through direct transcriptional repression mediated by the Polycomb group protein enhancer of zeste homolog 2 (EZH2). Upon depletion of EZH2 by RNA interference, SPRY4-IT1 expression was restored, and transfection of SPRY4-IT1 into NSCLC cells resulted in a significant antitumoral effect, both in culture and in xenografted nude mice. Moreover, overexpression of SPRY4-IT1 was found to have a key role in the epithelial-mesenchymal transition through the regulation of E-cadherin and vimentin expression. |
| Pubmed ID | 24967960 |
| Year | 2014 |
| Title | EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. |
External Links
| Links for SPRY4-IT1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |